Moderna is poised to seek regulatory approval for its mRNA flu vaccine following a successful Phase III trial. The vaccine, known as mRNA-1010, demonstrated superior efficacy compared to the current standard flu vaccine, marking a significant advancement in influenza prevention.
The study, which enrolled 40,805 participants across 11 countries, focused on adults aged 50 and older. It assessed the relative vaccine efficacy (rVE) of mRNA-1010 against a licensed standard-dose seasonal influenza vaccine. The results revealed an rVE of 26.6%, indicating a notable improvement over existing options.
Detailed Findings and Implications
The pivotal trial (NCT06602024) highlighted the vaccine’s effectiveness against multiple flu strains. Each strain within the vaccine, including A/H1N1, A/H3N2, and the B/Victoria lineages, showed robust efficacy with rVEs of 29.6%, 22.2%, and 29.1% respectively. These findings were consistent across various subgroups, regardless of age, risk factors, or previous influenza vaccination status.
“The severity of this past flu season underscores the need for more effective vaccines. An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for Covid-19 combination vaccines.” — Stéphane Bancel, Moderna CEO
Moderna’s mRNA-1010 also demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all included strains in a previous Phase III trial. This was in comparison to both high-dose and standard-dose licensed seasonal influenza vaccines.
Safety and Regulatory Pathway
The safety profile of mRNA-1010 was consistent with earlier studies, with most adverse events being mild. Injection site pain was the most commonly reported side effect. With these promising results, Moderna plans to engage with regulatory bodies to file submissions for mRNA-1010 approval.
This development comes at a turbulent time in the vaccine sector. Recently, US health secretary Robert F. Kennedy, Jr. made headlines by dismissing all members of the Advisory Committee on Immunization Practices (ACIP), replacing them with individuals known for their vaccine skepticism and criticism of Covid-19 vaccines and related public health measures.
Broader Context and Future Prospects
The ACIP plays a crucial role in advising the US Centers for Disease Control and Prevention on vaccination schedules. The current upheaval in this committee could have significant implications for vaccine policy and public health strategy in the United States.
Moderna’s advancement in mRNA technology not only represents a leap forward in flu prevention but also opens the door for future innovations, such as combination vaccines that could simultaneously protect against influenza and Covid-19. This potential for rapid adaptation to circulating strains could transform how flu vaccines are developed and deployed in the future.
As Moderna prepares to submit its findings to regulatory authorities, the healthcare community watches closely. The approval of mRNA-1010 could set a new standard in flu vaccination and bolster preparedness for future pandemics.
Stay informed with our daily news round-up and gain an edge with our industry insights. Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards, celebrating innovation, leadership, and impact in the field. Submit your nomination today to gain global recognition.
